Be Ready for Camzyos for Obstructive Hypertrophic Cardiomyopathy
April 2023
You’ll hear about Camzyos (mavacamten), the first med approved for “obstructive hypertrophic cardiomyopathy.”
This genetic heart disease affects about 1 in 500 people.
Obstructive hypertrophic cardiomyopathy causes the left ventricle muscles to become thick and stiff...slowing blood flow to the aorta and causing shortness of breath, chest pain, and fatigue.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive